Chemoprotective and Antioxidant Activities of Methanolic Extract of Amaranthus Spinosus Leaves on Paracetamol Induced Liver Damage in Rats
DOI:
https://doi.org/10.5457/ams.v39i2.159Keywords:
Amaranthus spinosus leaves, chemoprotective, paracetamol, antioxidant activityAbstract
Objective: Amaranthus spinosus Linn. (Amaranthaceae), the leaves were boiled without salt and consumed for 2−3 days to cure jaundice used by tribal of Kerala (India). Methanol extract of whole plant of A. spinosus Linn, (MEAS) was screened for hepatoprotective potency against paracetamol (PCM) (3 gm/kg. o.p.) induced-liver damage in Wistar rats at dose of 200 and 400 mg/kg respectively. Materials and methods: A. spinosus was collected from surroundings of chickballapur, Karnataka (India). Whole plant was extracted with methanol. Hepatoprotective activity of MEAS was evaluated in PCM induced hepatotoxicity in Wistar rats by measuring liver marker serum enzymatic levels of serum glutamate oxaloacetate transaminase (AST), serum glutamate pyruvate transaminase (ALT), albumin (ALB), total protein (TP), total bilirubin, direct bilirubin levels and the markers for oxidative defense namely malondialdehyde (MDA), reduced glutathione (GSH), catalase (CAT) and total thiols (TT). Histopathological studies of liver were done to assess the cellular damage. Results: The results of our study showed significant (P<0.001) protection against PCM induced hepatic damage in experimental animals following the administration of MEAS. Our results were compared with silymarin (100 mg/kg), a known hepatoprotective drug. Conclusions: This presence of amino acids, flavonoids and phenolic compounds in the MEAS might be responsible for its marked chemoprotective and antioxidant activities in paracetamol induced-liver damage in Wistar rats.
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
